Lian­Bio an­nounces terms for IPO next week; NIH and White House of­fi­cials dis­cuss hy­po­thet­i­cal bio-med re­search agency

Lian­Bio, a biotech that has op­er­a­tions in both the US and Chi­na, an­nounced the terms yes­ter­day for its ini­tial pub­lic of­fer­ing.

The biotech plans to raise $325 mil­lion by of­fer­ing 20.3 mil­lion shares priced be­tween $15 and $17.

At the mid­point of the pro­posed range, Lian­Bio could com­mand a ful­ly di­lut­ed mar­ket val­ue of $1.8 bil­lion, based on a num­ber of ex­pect­ed out­stand­ing shares.

The two year old biotech has fo­cused on in-li­cens­ing and com­mer­cial­iza­tion of ther­a­peu­tics in Chi­na, Hong Kong, Tai­wan, Macau and oth­er Asian mar­kets. The com­pa­ny cur­rent­ly has nine pro­grams across five ther­a­peu­tic ar­eas, in­clud­ing on­col­o­gy, car­dio­vas­cu­lar, and in­flam­ma­to­ry dis­eases.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER